Characteristics and outcomes of cases of children and adolescents with 1

- pediatric inflammatory multisystem syndrome in a tertiary care center 2
- in Mexico City 3
- Ricardo Gil Guevara ¹†, María de Lourdes Marroquín Yáñez²†, Rodolfo Norberto Jiménez-4
- Juárez^{3,4}, Víctor Olivar Lopez¹, Adrián Chávez Lopez², Juan José Luis Sienra Monge⁵, 5
- Lourdes Maria del Carmen Jamaica Balderas⁶, Silvia Alexandra Martínez Herrera¹, Clemen 6
- 7
- Domínguez-Barrera³, Julio Erdmenger Orellana⁷, Horacio Márquez González⁸, Miguel Klünder-Klünder⁹, Jaime Nieto Zermeño¹⁰, Mónica Villa Guillen¹⁰, Nadia González García¹¹ *, 8
- Maria F Castilla-Peon¹² * 9
- †These authors have contributed equally to this work and share first authorship 10
- *These authors have contributed equally to this work and are both corresponding authors 11
- ¹ Emergency Medicine Department, Hospital Infantil de Mexico Federico Gomez Instituto Nacional 13
- de Salud, Mexico City, Mexico 14

12

- ² Pediatric Intensive Care Unit, Hospital Infantil de Mexico Instituto Nacional de Salud, Mexico 15
- City, Mexico³ Infectious Diseases Department, Hospital Infantil de Mexico Federico Gomez Instituto 16
- Nacional de Salud, Mexico City, Mexico. 17
- ³ Department of Infectious Diseases, Hospital Infantil de Mexico Federico Gomez Instituto Nacional 18
- 19 de Salud, Mexico City, Mexico.
- ⁴ Department of Pediatrics, Infectious Diseases Hospital, UMAR National Medical Center "La Raza", 20
- Instituto Mexicano del Seguro Social, Ciudad de Mexico, Mexico 21
- 22 ⁵ Ambulatory Pediatrics, Hospital Infantil de Mexico Federico Gomez Instituto Nacional de Salud
- Instituto Nacional de Salud, Mexico City, Mexico. 23
- ⁶ Respiratory Medicine Department, Hospital Infantil de Mexico Federico Gomez Instituto Nacional 24
- 25 de Salud, Mexico City, Mexico.
- ⁷ Cardiology Department, Hospital Infantil de Mexico Federico Gomez Instituto Nacional de Salud, 26
- 27 Mexico City, Mexico
- ⁸ Department of Clinical Research, Hospital Infantil de Mexico Federico Gomez Instituto Nacional de 28
- Salud, Mexico City, Mexico 29
- ⁹ Research Division, Hospital Infantil de Mexico Federico Gomez Instituto Nacional de Salud, 30
- Mexico City, Mexco 31
- ¹⁰ Hospital Infantil de Mexcio Federico Gomez Instituto Nacional de Salud, Mexico City, Mexico 32
- Neruosciences Research Laboratory, Hospital Infantil de Mexico Federico Gomez Instituto 33
- Nacional de Salud, Mexico City, Mexico 34
- ¹² Research Division, Hospital Infantil de Mexico Federico Gomez Instituto Nacional de Salud. 35
- Mexico City, Mexico 36

37 38

41

- * Correspondence:
- Maria F. Castilla-Peon fernandacastillapeon@gmail.com 39
- Nadia Gonzalez-García nadia.him@gmail.com 40

Abstract

42

- 43 Background: pediatric inflammatory multisystem syndrome (PIMS) is a complication of severe acute
- 44 respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in children that resembles Kawasaki
- 45 syndrome and poses children at high risk of cardiorespiratory instability and/or cardiac damage. This
- study aims to describe the clinical presentation and outcomes of patients with PIMS in Mexico City.
- 47 Methods: this was an observational study (May 1, 2020, to September 30, 2021) of children with
- 48 PIMS according to Centers of Disease Control and Prevention case definition criteria, hospitalized in
- 49 a single tertiary care pediatric center in Mexico City. Demographic characteristics, epidemiological
- data, medical history, laboratory tests, cardiology evaluations, treatment, and clinical outcomes were
- 51 analyzed.
- Results: Seventy-five cases fulfilled case-definition criteria for PIMS (median age 10.9 years, IQR:
- 53 5.6-15.6). Fifteen (20%) had a severe underlying disease. Forty-eight cases (64%) were admitted to
- 54 the intensive care unit, 33 (44%) patients required invasive mechanical ventilation, and 39 (52%)
- received vasopressor support. Two distinct groups of patients were identified: cluster 1 (n=60) who
- had rash or gastrointestinal symptoms and cluster 2 (n=15) with predominantly respiratory
- 57 manifestations. Two cases (2.7%) died, both with severe underlying conditions. Five cases (6.7%)
- developed coronary aneurysms, all of them from cluster 1.
- 59 Conclusion: clinical manifestations and outcomes are in general comparable what has been
- previously reported in international series. In our series, there was a high proportion of patients with
- severe respiratory involvement and positive RT-PCR SARS-CoV-2 and a low frequency of coronary
- aneurysms which suggests a possible higher proportion of children with severe acute COVID-19 in
- our included cases.
- 64 Keywords: pediatric multisystem inflammatory disease, COVID-19, SARS-CoV-2, children,
- 65 coronary aneurysms, Mexico.

Introduction

66

67

- 68 Infection by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) usually has a mild
- 69 clinical presentation in children. However, in rare cases, children can be severely affected and have
- 70 clinical manifestations different from adults. In April 2020, some reports described a clinical
- 71 syndrome similar to Kawasaki disease or toxic shock syndrome temporally associated with current or
- recent SARS-CoV-2 infection in the pediatric population(1). Since then, this syndrome has been
- 73 recognized worldwide and named pediatric inflammatory multisystem syndrome (PIMS) or
- 74 multisystem inflammatory syndrome in children (MIS-C). (2–6).
- 75 PIMS case definition varies slightly between different health agencies (7–9) and is likely to change
- over time. Criteria include fever, inflammatory marker elevation, multisystem organ involvement,
- evidence of current or recent SARS-CoV-2 infection, and exclusion of alternative diagnoses. Besides
- 78 the need for hospitalization for life support, an outcome of concern is possible myocardial and
- 79 coronary artery involvement similar to those observed in Kawasaki disease (10–12).

- PIMS incidence has been estimated to be approximately 3-5 per 10,000 individuals younger than 21
- years of age infected with SARS-CoV-2. Black and Hispanic ethnicities have been associated with a
- 82 higher incidence (13).
- 83 Epidemiological description of PIMS has been difficult because of varying awareness of the
- 84 condition in different clinical scenarios and because of the diversity of clinical manifestations.
- 85 Besides, there is an overlap between the clinical manifestations of severe acute COVID-19 and PIMS
- 86 (10). Current PIMS case definition is purposely broad and unspecific in the aim to collect the
- 87 maximum information about this phenomenon. However, increasing evidence suggests the existence
- of different phenotypes of PIMS, the more clearly defined of them being a Kawasaki-like syndrome,
- 89 a Toxic Shock-like syndrome, and a predominantly respiratory syndrome which might have different
- 90 pathogenesis and clinical outcomes. (14–16).
- 91 This study aims to describe the clinical characteristics and outcomes of PIMS cases admitted to a
- 92 tertiary care pediatric center in Mexico City. An attempt was made to define different subgroups of
- patients who otherwise fulfilled case definition criteria for PIMS.

Methods

94

- 95 Study design. This is a cross-sectional analysis of PIMS cases diagnosed in "Hospital Infantil de
- 96 México Federico Gómez" (Federico Gómez Mexico Children's Hospital), a tertiary care pediatric
- 97 facility officially designated to attend patients with severe SARS-CoV-2 infection in the population
- younger than 18 without public or private health insurance in Mexico City.
- 99 Possible PIMS cases were identified in the emergency room, were transferred from other health care
- facilities directly to the Intensive Care Unit or were identified by treating physicians in the general
- 101 hospitalization ward for COVID-19 patients. Cases were evaluated to determine if they met the CDC
- 102 PIMS case definition(7). In brief, criteria included the presence of fever, the elevation of
- inflammatory markers, signs of involvement of at least two organic systems requiring hospitalization,
- and evidence of recent SARS-CoV-2 exposure or infection. Patients were excluded if they had
- another plausible explanation for the illness. When there was uncertainty about an alternative
- diagnosis, the complete case file was reviewed by an expert panel which included an infectious
- disease and a critical care specialist, and a consensus was reached. Detailed inclusion criteria are
- specified in Chart 1.
- 109 Data collection. Clinical and laboratory data were extracted from the clinical file and included
- demographics, underlying medical conditions, clinical manifestations, laboratory values,
- management, and outcomes. For laboratory values with more than one measurement, the worst value
- measured within the first three days of hospitalization was registered. Vital support management
- 113 (respiratory support and vasopressor utilization), intravenous immune globulin, systemic steroids,
- and anticoagulant therapy were documented as the main therapeutic interventions. Outcomes of
- interest were intensive care unit (ICU) admission, length of ICU and hospitalization stay, need for
- invasive mechanical ventilation, vasopressor support, myocardial depression (left ventricular ejection
- fraction < 55%), coronary aneurysms (coronary artery diameter z-score >= 2.5), or dilatation (z-score
- 118 2> <2.5) on the echocardiographic evaluation performed during hospitalization, and in-hospital
- mortality. Markers with more than 20% missing data were not analyzed.
- For this study, severe respiratory involvement was defined as infiltrates on chest X-ray or computed
- tomography plus the need for oxygen administration with a non-re-breathable mask or a higher

It is made available under a CC-BY-NC-ND 4.0 International outcomes in Mexico City

- oxygen concentration device. The variable "gastrointestinal symptoms" was defined as the presence
- of at least one of the following: abdominal pain, diarrhea or emesis.
- The study center has an important population of patients with severe underlying diseases. To have a
- picture more alike general population, we performed a sub-analysis with the exclusion of cases with
- severe underlying diseases (i.e., cancer and other forms of immunosuppression, neuromuscular
- disability, chronic respiratory disease except for asthma, congenital cardiopathies, and chronic kidney
- 128 failure).
- 129 Statistical analysis. Descriptive analysis was undertaken in STATAv.14.0 (StataCorp, Tx).
- 130 Categorical variables are reported as frequencies and continuous variables as medians and
- interquartile ranges (IQR). Analysis was performed in the whole sample and three subgroups. In the
- 132 first subgroup, cases with severe underlying conditions were excluded. The other two groups were
- derived using latent class analysis (LCA). Two class LCA were conducted using the R software
- package "poLCA" (17) with 100 iterations to identify the clusters. The indicator variables used in
- 135 LCA were the presence or absence of severe respiratory involvement, rash, and gastrointestinal
- symptoms. The fit of each model was assessed using a Bayesian Information Criterion score.
- 137 The ethics review board of Federico Gómez Mexico Children's Hospital authorized the analysis and
- publication of de-identified data (Reg: HIM2020-031).
- 139 Results
- 140 Clinical departments sent 167 reports of cases with probable PIMS admitted to the Hospital from
- May 1, 2020, through September 30, 2021. For reference, during this period, 8193 real time
- polymerase chain reaction (RT-PCR) tests for SARS-CoV-2 tests were performed in the study center,
- 143 from which 837 had a positive result.
- From the 167 received reports, 42 were from the emergency department, 34 from the intensive care
- unit, and 91 from the infectious disease department. Duplicated reports were eliminated (n=23), 23
- reports failed to meet inclusion criteria and 46 were excluded because an alternative etiology was
- found to explain the clinical manifestations after the comprehensive review of the case's file and
- 148 consensus among researchers. All subsequent analyses were performed in the remaining 75 cases
- unless otherwise specified.
- The median (interquartile range, IQR) age was 10.9 (5.6-15.6) years old and 52% were female. At
- least one underlying condition was found in 45.3% of the population, including obesity (25%),
- cancer (9%), neuromuscular (8%), and respiratory (7%) diseases among others (Table 1).
- In addition to fever, the most common clinical manifestations were cough (52%), conjunctivitis
- 154 (50.6%), abdominal pain (51%), rash (48%), headache (45.3%), and diarrhea (44%). The median
- 155 (IQR) duration of symptoms before admission was 7 (4-9) days. About 51% had lower respiratory
- symptoms, 85% had pulmonary infiltrates in the radiograph or computed tomography, and 65.3%
- required oxygen administration with a non-rebreathable mask, high flow nasal cannula, or
- mechanical ventilation. Vasopressor support was used in 52% of cases, and about 40% had a left
- ventricular ejection fraction < 55% on echocardiography. Median values for markers of
- inflammation, coagulation, and system damage are summarized in table 1.

- 161 Three subgroups were analyzed independently. In the first subgroup (n=60), 15 cases with a severe
- underlying disease were excluded. Clinical manifestations and outcomes did not differ significantly
- from those observed in the total sample (Table 1 and 2)
- The second (n=60) and third (n=15) subgroups were derived from LCA which identified two classes
- of patients: cluster 1 (n=60) composed of patients with rash and/or gastrointestinal symptoms, and
- cluster 2 (n=15) with predominant cardiorespiratory involvement without a rash or gastrointestinal
- symptoms. Despite the reduced number of cases in cluster 2, some differences are evident: cluster 2
- cases were more prone to have a positive RT-PCR test (76% vs 100%, p= 0.04) and less so to have a
- positive serology test (0 vs 54%, p<0.001). An underlying medical condition was also more frequent
- in cluster 2 (80 vs 36.7%, p=0.003), especially a severe one (47 vs 13%, p=0.008) such as cancer,
- 171 neuromuscular disability, or a chronic respiratory condition. (Table 1). Cluster 1 patients tended to
- have higher levels of inflammation markers, though the difference was statistically significant only
- 173 for the neutrophil count and D-Dimer concentration.
- About treatment, 45.3%, 64%, and 63% of cases received intravenous immune globulin, systemic
- steroids, and anticoagulation therapy respectively, much more frequently in the cluster 1 group.
- 176 (Table 2)
- 177 Regarding outcomes, two (2.7%) patients died. Both had severe underlying diseases; the first one had
- a medulloblastoma and died two weeks after the antineoplastic chemotherapy dose and the second
- one had chronic kidney failure and was on dialytic replacement therapy. One death occurred in each
- cluster group. About 44% of cases needed mechanical ventilation, 52% of cases required vasopressor
- support while 40% had a depressed ventricular function. (Table 2)
- All cases had an echocardiographic evaluation during hospitalization. Five cases (6.7%) had coronary
- aneurysms. Notably, all cases with aneurysms were in Cluster 1. No patient had a coronary diameter
- with a z-score between 2.0 and 2.5. Myocardial involvement (left ventricular ejection fraction <
- 185 55%) was observed in 30(40%) of cases. Intensive care unit (ICU) admission occurred in 64% of
- cases with a median (IQR) length of stay there of 5 (3-8) days and a length of hospital stay of 7(4-
- 13). There was a tendency of cluster 2 patients to remain longer in ICU and in hospital. (Table 2)

188 **Discussion**

- The present study describes the largest cohort of patients with PIMS in the Mexican population to
- date, as long as we are aware. Most clinical characteristics and outcomes of our series were like those
- described in large international reports. The median age of our sample was some years older than
- most series. Prevalence of underlying medical conditions, including obesity was similar to the
- reported in the United States and Latin America (10,16,18–20), except for cancer which is relatively
- 194 frequent in our total sample, reflecting the characteristics of the population regularly attending the
- study center. Cardiac dysfunction, vasopressor requirements, rash, and gastrointestinal symptoms
- were comparable to those reported elsewhere, so as ICU admissions, length of hospital stay, and
- length of ICU stay. The death rate of 2.7% (binomial 95% confidence interval: 0.3-9.3%) was similar
- 198 to the previously reported (3.5,10,14,18,21).
- Our population had a relatively high frequency of lower and serious respiratory involvement in
- comparison with most of the other series. Besides, in our sample, serology was performed in only
- 201 55% of cases, so the evidence of SARS-CoV-2 infection in our population is mostly by RT-PCR
- 202 (80% positivity rate). These findings might point toward a higher proportion of acute severe SARS-
- 203 CoV-2 infection vs a theoretical late-onset post-infectious syndrome in our sample compared to

- other case series where respiratory involvement and RT-PCR positive rate was lower (3,5,10,14,18).
- 205 Current PIMS diagnostic criteria does not exclude acute severe COVID-19; this overlap between
- both clinical presentations has been previously discussed (10,16).
- 207 On the other hand, the frequency of coronary aneurysms in our study was relatively low (6.7%).
- Aneurysm frequency is heterogeneous among reports, varying from 6.7 to 23.3% (14,18,19,21). This
- 209 probably reflects the lack of specificity on the PIMS case-definition criteria and the variability of the
- 210 cut-point for some inflammatory markers used in different reports. Most case series are derived from
- active or passive surveillance, either retrospectively or prospectively. Many of them do not inform a
- 212 cut-point for inflammatory markers concentration, or clinical symptoms and it is assumed that the
- 213 higher limit of the normal reference range was used. This probably explains the high frequency of
- coronary aneurysms (23.3%) found by Flood et al., in the United Kingdom, their study having a very
- 215 high cut-point for CRP (100mg/L) and requiring "acute abdomen" and very specific dermatological
- 216 findings, not only "abdominal pain" or "rash" as criteria for gastrointestinal or mucocutaneous
- involvement respectively (14). Stringency in diagnostic criteria automatically excludes a high
- 218 proportion of potential cases keeping a more homogeneous and severely affected population.
- Notably, none of the five aneurysm cases of our series had a serious underlying disease and all of
- 220 them belonged to cluster 1 (Mucocutaneous/gastrointestinal predominant symptoms). Although ours
- 221 was a small sample to make any inference, it supports the increasing awareness about the existence of
- different clinical phenotypes. Godfred-Cato et al.(15), and later Geva et. al(16), identified three
- classes of patients: 1) a seriously ill group with significant cardiovascular involvement, multiple
- organ dysfunction, a pronounced elevation of inflammatory markers who tended to have positive
- serology for SARS-CoV-2, a second group with predominant respiratory involvement and high RT-
- PCR positivity rate that resembles our cluster 2 group, and the third group with predominant
- 227 Kawasaki- like mucocutaneous findings. Meanwhile, Flood et al. also identified three PIMS
- 228 phenotypes using cluster analysis: PIMS with Kawasaki disease-like presentation, PIMS with
- findings of Kawasaki disease and shock, and PIMS without any of these features (14) and consensus
- derived clinical recommendations have been generated accordingly (22). In all three cluster
- analyses, coronary artery aneurysms are more frequent in groups with Kawasaki-like features and
- higher levels of inflammatory markers, which in our cluster analysis corresponds to Cluster 1. It
- 233 might be important to differentiate the clinical subtypes diagnosed as PIMS under the umbrella of
- 234 CDC and WHO case definition criteria, since probably not all of them benefit from the same
- therapeutic interventions. The role of inflammation along all spectrum of severe illness associated
- with SARS-CoV-2 infection should be deeply studied, including its role in myocardial disfunction
- since it is a frequent complication both in adults with COVID-19 and children with PIMS. (23)
- A limitation of this study, as in others, is the method for identification of included cases for analysis
- depending on spontaneous reports by treating clinicians. In the future, a prospective multicentric
- 240 cohort design with clear-cut criteria for subclassification of every patient fulfilling the broad clinical
- criteria after SARS-CoV-2 infection would provide more information on the outcomes and possible
- associated factors.

Conclusions

243

- 244 Epidemiology of PIMS cases observed in our center is comparable to the reported elsewhere,
- 245 although our series included a high proportion of patients with an acute-like respiratory phenotype.
- 246 Coronary aneurysms are infrequent and usually present in previously healthy patients with rash or

- 247 gastrointestinal symptoms. The death rate is alike the reported elsewhere and occurred in patients
- with severe underlying diseases.
- We agree with other researchers that underneath the umbrella of case definition for criteria for
- 250 COVID-19 at least two groups of patients can be identified according to their clinical presentation.
- 251 Standardized criteria for sub-classification of PIMS cases need to be developed, since different
- 252 phenotypes might have different pathophysiology, different outcomes, and possibly require different
- 253 management. Clinical trials are needed to evaluate therapeutic interventions in different PIMS
- 254 phenotypes.
- 255 Conflict of Interest
- 256 The authors declare that the research was conducted in the absence of any commercial or financial
- relationships that could be construed as a potential conflict of interest.
- 258 Data Availability
- All data produced in the present study are available upon reasonable request to the authors
- **260 Author Contributions**
- All authors contributed with study planning, design and review of the final manuscript. RGG,
- MLMY, RNJJ, VBOL contributed with data collection. HMG coordinated the research team. MFCP
- and NGG performed data analysis and the writing of the manuscript.
- 264 Funding
- 265 This study was funded by Hospital Infantil de México Federico Gómez
- 266 **Data Availability Statement**
- The datasets generated for this study can be requested to corresponding authors.
- 268 1. Riphagen S, Gomez X, Gonzalez-Martinez C, Wilkinson N, Theocharis P. Hyperinflammatory shock in children during COVID-19 pandemic. Lancet. 2020;395(10237):1607–8.
- 270 2. Cheung EW, Zachariah P, Gorelik M, Boneparth A, Kernie SG, Orange JS, et al. Multisystem
- 271 Inflammatory Syndrome Related to COVID-19 in Previously Healthy Children and
- Adolescents in New York City. JAMA J Am Med Assoc. 2020;324(3):294–6.
- 273 3. Whittaker E, Bamford A, Kenny J, Kaforou M, Jones CE, Shah P, et al. Clinical
- 274 Characteristics of 58 Children with a Pediatric Inflammatory Multisystem Syndrome
- Temporally Associated with SARS-CoV-2. JAMA J Am Med Assoc. 2020;324(3):259–69.
- 276 4. Licciardi F, Pruccoli G, Denina M, Parodi E, Taglietto M. SARS-CoV-2 Induced Kawasaki-
- 277 Like Hyperin fl ammatory Syndrome ☐: A Novel COVID Phenotype in Children. Pediatrics.
- 278 2021;146(2):1–5.
- 279 5. Dufort EM, Koumans EH, Chow EJ, Rosenthal EM, Muse A, Rowlands J, et al. Multisystem
- Inflammatory Syndrome in Children in New York State. N Engl J Med. 2020;383(4):347–58.

- 281 6. Assessment RR. European Centre for Disease Prevention and Control Country Experts. Rapid
- 282 Risk Assessment: Paediatric inflammatory multisystem syndrome and SARS-CoV-2 infection
- in children. https://www.ecdc.europa.eu/sites/default/files/documents/covid-19-risk-
- 284 assessment. 2020;(May):1–18.
- 7. HAN Archive 00432 | Health Alert Network (HAN) [Internet]. [cited 2021 Dec 14].
- Available from: https://emergency.cdc.gov/han/2020/han00432.asp
- 8. Royal College of Paediatrics and Child Health. Guidance paediatric multisystem inflammatory syndrome temporally associated with Cov-19. R Coll Paediatr Child Heal. 2020;1–6.
- 9. Jiang L, Tang K, Levin M, Irfan O, Morris SK, Wilson K, et al. COVID-19 and multisystem inflammatory syndrome in children and adolescents. Lancet Infect Dis. 2020;20(11):e276–88.
- 291 10. Feldstein LR, Tenforde MW, Friedman KG, Newhams M, Rose EB, Dapul H, et al.
- 292 Characteristics and Outcomes of US Children and Adolescents with Multisystem
- 293 Inflammatory Syndrome in Children (MIS-C) Compared with Severe Acute COVID-19.
- 294 JAMA J Am Med Assoc. 2021;325(11):1074–87.
- 295 11. Son MBF, Murray N, Friedman K, Young CC, Newhams MM, Feldstein LR, et al.
- 296 Multisystem Inflammatory Syndrome in Children Initial Therapy and Outcomes. N Engl J
- 297 Med. 2021;385(1):23–34.
- 298 12. Davies P, Evans C, Kanthimathinathan HK, Lillie J, Brierley J, Waters G, et al. Intensive care
- admissions of children with paediatric inflammatory multisystem syndrome temporally
- associated with SARS-CoV-2 (PIMS-TS) in the UK: a multicentre observational study. Lancet
- 301 Child Adolesc Heal. 2020;4(9):669–77.
- 302 13. Payne AB, Gilani Z, Godfred-Cato S, Belay ED, Feldstein LR, Patel MM, et al. Incidence of
- 303 Multisystem Inflammatory Syndrome in Children Among US Persons Infected With SARS-
- 304 CoV-2. JAMA Netw Open [Internet]. 2021 Jun 1 [cited 2021 Dec 14];4(6):e2116420–
- 305 e2116420. Available from:
- 306 https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2780861
- 307 14. Flood J, Shingleton J, Bennett E, Walker B, Amin-Chowdhury Z, Oligbu G, et al. Paediatric
- 308 multisystem inflammatory syndrome temporally associated with SARS-CoV-2 (PIMS-TS):
- Prospective, national surveillance, United Kingdom and Ireland, 2020. Lancet Reg Heal Eur
- 310 [Internet]. 2021 Apr 1 [cited 2021 Dec 14];3. Available from:
- 311 http://www.thelancet.com/article/S2666776221000521/fulltext
- 312 15. Godfred-Cato S, Bryant B, Leung J, Oster ME, Conklin L, Abrams J, et al. COVID-19-
- Associated Multisystem Inflammatory Syndrome in Children United States, March-July
- 2020. MMWR Morb Mortal Wkly Rep [Internet]. 2020 Aug 14 [cited 2021 Dec
- 315 14];69(32):1074–80. Available from: https://pubmed.ncbi.nlm.nih.gov/32790663/
- 316 16. Geva A, Patel MM, Newhams MM, Young CC, Son MBF, Kong M, et al. Data-driven
- 317 clustering identifies features distinguishing multisystem inflammatory syndrome from acute
- 318 COVID-19 in children and adolescents. EClinicalMedicine [Internet]. 2021;40:09–10.
- 319 Available from: https://doi.org/10.1016/j.eclinm.2021.101112

Linzer DA, Lewis JB. poLCA: An R package for polytomous variable latent class analysis. J
 Stat Softw. 2011;42(10):1–29.

- 322 18. Belay ED, Abrams J, Oster ME, Giovanni J, Pierce T, Meng L, et al. Trends in Geographic 323 and Temporal Distribution of US Children with Multisystem Inflammatory Syndrome during 324 the COVID-19 Pandemic. JAMA Pediatr. 2021;175(8):837–45.
- States U, July M, Godfred-cato S, Bryant B, Leung J, Oster ME, et al. COVID-19–Related
 Multisystem Inflammatory Syndrome in Children. AAP Gd Rounds. 2020;44(3):30–30.
- Torres JP, Izquierdo G, Acuña M, Pavez D, Reyes F. Multisystem inflammatory syndrome in children (MIS-C): Report of the clinical and epidemiological characteristics of cases in Santiago de Chile during the SARS-CoV-2 pandemic Juan. Int J Infect Dis.
 2020;2020(100):75–81.
- 331 21. Antúnez-Montes OY, Escamilla MI, Figueroa-Uribe AF, Arteaga-Menchaca E, Lavariega-332 Saráchaga M, Salcedo-Lozada P, et al. COVID-19 and Multisystem Inflammatory Syndrome 333 in Latin American Children: A Multinational Study. Pediatr Infect Dis J. 2020;40(1):1–6.
- Harwood R, Allin B, Jones CE, Whittaker E, Ramnarayan P, Ramanan A V., et al. A national consensus management pathway for paediatric inflammatory multisystem syndrome temporally associated with COVID-19 (PIMS-TS): results of a national Delphi process. Lancet Child Adolesc Heal. 2021;5(2):133–41.
- 23. Eiros R, Barreiro-Pérez M, Martín-García A, Almeida J, Villacorta E, Pérez-Pons A, et al.
 Pericardial and myocardial involvement after SARS-CoV-2 infection: a cross-sectional descriptive study in healthcare workers. Rev Española Cardiol (English Ed. 2021;

341

	1. Case definition of	THENATOF PHVIS			
1.					
2.	Elevation of	At least one of the following:			
	inflammation markers	• C-Reactive Protein (CRP) >5mg/L			
		• Procalcitonin > 0.15 ng/ml			
		• Ferritin > 300 mcg/L			
		• Fibrinogen > 400 mg/dl			
		• D-Dimer >560 ng/ml			
		• Neutrophils > 7500 cells/mcl			
		• Lymphopenia: <2 years: <4000, 2-3 years: <3000, >4 years: <1500 cells/mcl			
		• Albumin < 3 g/dl			
3.	At least two systems	3.1 Cardiovascular. At least one of the following:			
	involved	Required vasoactive drug			
		• Left ventricular ejection fraction < 55%			
		3.2 Respiratory. At least one of the following:			
		Supplementary oxygen with non-rebreathable mask or higher			
		oxygen concentration device.			
		 Oxygen saturation <90% 			
		 Pulmonary infiltrates in chest X-Ray or Computed Tomograph 			
		3.3 Neurologic. At least one of the following:			
		· · · · · · · · · · · · · · · · · · ·			
		• Glasgow score < 14 if not sedated			
		Meningismus			
		• Seizures			
		3.4 Hematologic. At least one of the following:			
		• Plateletes< 150 000 cells/mcl			
		• Prothrombin time >14 sec			
		3.5 Gastrointestinal. At least one of the following:			
		Abdominal pain			
		Vomit			
		 Diarrhea 			
		 Alanineaminotransferase (ALT) > 90 U/L 			
		3.6 Mucocuteneous. At least one of the following:			
		• Rash			
		Extremity edema			
		Desquamation			
		Mucosal inflammation			
		• Conjuntivitis 3.7 Renal.			
1	Hospitalization	• Creatinine > twice upper limit of the reference range for age			
<u>4.</u> 5.	No alternative	No positive blood culture during the first 48 hours in the			
٥.		The positive close culture curing the lines to hours in the			
	diagnosis	hospital			
		In uncertain cases, complete file review and consensus by an expert panel.			
	Dragant or recent	expert panel.			
6.	Present or recent	At least one of the following			
	infection by SARS-	• Positive RT-PCR ¹ for SARS-COV2			
	COV2	 Positive serology for SARS-COV2 			
		• Contact with a confirmed positive COVID-19 case in the last			
		four weeks.			

Table.1 Clinical presentation of cases with PIMS										
·	Totalpopulation(N =75) ¹	Without serious underlying disease ² (N=60) ¹	Cluster 1 With GIS ³ or Rash (N=60) ¹	Cluster 2 Predominant respiratory (N=15) ¹						
Female sex -no.(%)	39 (52%)	33(55%)	33 (55%)	6 (40%)						
Age - median (IQR)	10.9 (5.6-15.6)	10.6 (5.5-15.0)	10.3 (5.7-13.5)	15.3 (5.4-16.6)						
Age group - n (%)										
<1 y	5 (6.7%)	5 (8.3%)	4(6.7%)	1 (6.7%)						
1-4 y	11 (17.3%)	9 (15%)	9 (15%)	2 (1.3%)						
5-9 y	13 (17.1%)	11 (18.3%)	12 (0.2%)	1 (6.7%)						
10-14 y	26 (34.7%)	21 (35%)	23 (38.3%)	3 (20%)						
15-18 y	20 (26.7%)	14 (23.3%)	12 (20%)	8 (53%)						
Days of sympthoms before admission	7(4-9)	7 (5-9)	6 (4-8)	7 (1-9)						
SARS-COV2 testing, No. (%)										
RT- PCR positive	57/71 (80%)	43/56 (76.8%)	44/58 (75.9%)	13/13 (100%)*						
Serology positive	25/41 (61%)	25/46 (54%)	25/46(54%)	0*						
Underlying medical conditions - no. (%)										
Obesity (BMI > 95° percentile)	18 (24%)	14 (23.0%)	12 (20%)	6 (40%)						
Respiratoriy	5 (6.7%)	3 (5%)	2 (3.3%)	3(20%)*						
Nerumomuscular	6 (8.0%)	0	2 (3.3%)	4 (26.7%)*						
Cardiovascular	3 (4%)	0	2 (3.3%)	1 (6.7%)						
Cancer	7 (9.3%)	0	2 (3.3%)	5 (33%)*						
Other, immunosupression	2 (3%)	0	1 (1.7%)	1 (6.7%)						
Othercomorbidity	10 (13.3%)	6 (10%) ⁴	8 (13.3%)	2 (13.3%)						
At least 1 underlyingcondition	34 (45.3%)	19 (31.2%)	22 (36.7%)	12 (80%)*						
Clinicalmanifestations – no.(%)	54 (45.570)	17 (31.270)	22 (30.770)	12 (00 /0)						
Cough	39(52%)	32 (53.3%)	33 (55%)	6 (40%)						
Rash	36 (48%)	33 (55%)	36 (60%)	0 (40%)						
Conjuntivitis		, ,	, ,							
Diarrhea	39 (50.6 %)	39 (52%)	37 (61.7%)	2 (13.3%)						
	33 (44%)	27 (45%)	33 (55%)	0						
Abdominal pain	38 (51%)	36 (60%)	38 (63.3%)							
Headache	34(45.3%)	25 (41.7%)	27 (45%)	7 (46.7%)						
Rinorrhea	24 (32%)	20 (33.3%)	19 (31.7%)	5 (33.2%)						
ResiratoryDistress	31 (41%)	24 (40%)	21 (35%)	10 (66.7%)*						
Lower respiratorysimptoms	41 (54%)	31 (51.7%)	29 (48.3%)	12 (80%)*						
Anosmia/Dysgeusia	7 (9.3%)	6 (10%)	4 (6.6%)	3 (20%)						
Arthralgias/Myalgias	14(18.7%)	11 (18.3%)	13 (21.7%)	1 (6.7%)						
OxygenSaturation<90%	30 (40%)	20 (33.3%)	22 (36.7%)	8 (53.3%)						
Laboratory values within 72 h of admission – median (IQR) / n.(%)										
Neutrophil count x10 ⁶ cells/mcl	6.1 (1.7-9.2)	7.1(3.1-10.1)	6-5 (1.9-9.8)	3.1(0.5-7.1)*						
Neutrofilia (>7500 cels/mm³)	29/74 (39.2 %)	27/59 (45.8%)	27/59 (45.8%)	2 (13.3%)*						
Neutropenia (<1000 ceks/mm³)	10 (13%)	6 (10%)	5 (8.3%)	5 (33%)*						
Lymphocyte count x10 ⁶ cells/mm ³	1.5 (0.5-2.4)	1.6 (0.8-2.1)	1.6 (0.6-2.8)	0.8 (0.4-1.8)						
Lymphopenia ⁵	43/73 (58.9 %)	33/58 (56.9%)	33/58 (56.9%)	10 (66.7%)						
Plateletsx 10 ³ cells/mm ³	162 (94-250)	166(110-271)	162 (105-235)	162 (43-330)						
Fibrinogen, mg/dl	510 (404-668)	558(431-724)	516 (412-671)	510 (361-669)						
Fibrinogen> 400 mg/dl	52 (69.3%)	44/56 (78.6%)	43 (71.7%)	9 (60%)						
Ferritinmcg/L	617 (407-1370)	559 (380-1110)	604 (417-1150)	1370 (325-6071)						
Ferritin> 300 mg/dl	53 (70.1%)	41 (68.3%)	46/55 (83.6%)	7/9 (77.7%)						
D-Dimer ng/L	2.6 (1.1-6.5)	2.9(1.2-8.8)	3.5(1.3-9.5)	0.8 (0.5-1.2)*						
D- Dimer> 560ng/ml (0.56 ng/L)	66/74 (89.2%)	55 (91.7%)	55/59 (93%)	11/15 (73.3%)*						
C-reactive protein (mg/L)	9.8 (4.5-18.9)	13.5 (6.1-19.9)	13.2 (5.9-19.1)	7.3 (0.7-17.7)						
C-reactive protein > 5mg/L	47/63 (74.6%)	41/50 (82%)	42/54 (77.8%)	5/9 (55.5%)						
Procalcitonin ng/ml	1.85 (0.5-6.3)	1.8(0.47-3.84)	2.1 (1.16-6.4)	0.37 (0.12-6.17)						
Procalcitonin > 0.15ng/ml	55/62 (88.7%)	43/50 (86%)	47/51 (92%)	8/11 (72.7%)						
Albumin< 3g/dl	45/71 (63.3%)	36/56 (64.3%)	40/57 (70.2%)	5/14 (35.7%)*						
127.										

¹N in the column heading was used to calculate proportions if not otherwise specified. For variables with missing data, denominators are reported in each cell. ²Excluded: cancerl, immunodeficency, neuromuscular, chronic respiratory disease except asthma, congenital cardiopathies, chronic kidney failure. ³GIS: Gastrointestinal sympthoms, includes abdominal pain, diarrhea, emesis. ⁴Trisomy 21 (n=1), Post recent appendicectomy (n=2), hypothyroidism (n=2), undernutrition (n=1). ⁵Lymphopenia: (<2 years: <4000, 2-3 years: <3000, >4 years: <1500 cells/mcl)

^{*}P<0.05, one-sided Fisher exact test/ Mann-Whitney test for comparison between cluster 1 and cluster 2.

	Total sample(N=75) ¹	Without serious	Cluster 1	Cluster 2	***
		underlying disease (N=60) ¹	With GIS or rash (N=60) ¹	Cluster 2 Predominant respiratory (N=15) ¹	p*
Treatment – no. (%)					
Intravenous immune globulin	34(45.3%)	32(53.3%)	33 (55%)	1 (6.7%)*	0.01
Systemic steroids	48 (64.0%)	43 (71.7%)	44 (73.3%)	4 (26.7%)*	0.001
Anticoagulation therapy	47 (62.7%)	40 (66.7%)	41 (68%)	6 (40%)*	0.04
Maximum ventilatory support needed - no (
Non-rebreather mask	8 (10.7%)	7 (11.7%)	1 (1.7%)	1 (6.7%)	
High flow nasal cannula	4 (5.3%)	2 (3.3%)	2 (3.3%)	2 (13.3%)	
Non-invasive mechanical ventilation	4 (5.3%)	4 (6.7%)	4 (6.7%)	0	
Invasive mechanical ventilation	33 (44 %)	25 (41.7%)	25 (41.7%)	9 (60%)	0.16
Any infiltrates in chest Rx or CT	60/71 (85%)	48/56 (85.7%)	45/56 (80%)	15 (100%)	0.06
Severe respiratory involvment ²	28 (37.3%)	21 (35%)	19 (31.7%)	9 (60%)	0.04
Cardiovascular involvement – no (%)	, ,	, ,	` '	, ,	
LVEF ³ <55%	30 (40.0%)	24 (40%)	22 (36.7%)	8 (53.3%)	0.18
LVEF<45%	6 (8.0%)	5 (8.3%)	6 (10%)	0	0.25
LVEF < 35%	0	0	0	0	
Coronary aneurysm (z score > 2.5)	5 (6.7%)	5(8.3%)	5 (8.3%)	0	0.32
Coronary dilatation (z score >2 - <2.5)	0	0	0	0	
Vasopressor support – no (%)	39 (52.0%)	30 (50%)	32 (53.3%)	7 (46.7%)	0.43
Hematologic involvement	50 (66.7%)	39 (65%)	39 (65%)	12 (80%)	
	37/72 (51.5%)	30 (50%)	<i>as</i> (<i>aa,a</i>)	-= (,-,	0.26
Platelets count <150 000 cell/mcl	29 (38.7%)	21 (35%)	24 (40%)	6 (40%)	1.0
Neurologic involvement ⁴	5 (6.7%)	5 (8.3%)	5 (8.3%)	0	0.32
Gastrointestinal involvement	60 (80%)	51 (85%)	57 (95%)	3 (20%)	< 0.001
Alanine Aminotransferase (ALT)	21/72 (29.2%)	16/58 (27.6%)	17/58 (29.3%)	4/14(28.5%)	0.62
Mucocutaneous involvement	64 (85.3%)	39 (65%)	58 (96.7%)	6 (40%)	< 0.001
· ·	19/74 (25.7%)	26.7%	19 (31.7%)	0 (40%)	0.001
Clinical outcomes- no.(%) / median (IQR)	17/14 (23.170)	20.770	17 (31.770)	U	0.01
ICU ⁶ admission	48 (64%)	37 (61%)	38 (63%)	10 (66.7%)	0.53
Length of ICU stay-d (n=48)	5 (3-8)	4(3-8)	4.5 (3-8.3)	7.5 (3.5-13.5)	0.33
Length of Hospital stay days	7 (4-13)	7(4-11)	7 (4-12)	10 (5-17)	0.23
Died	2 (2.7%)	0	1 (1.7%)	1 (6.7%)	0.36

¹ N in the column heading was used to calculate proportions if not otherwise specified. For variables with missing data, denominators are reported in each cell. Severe respiratory involvment was defined as oxygen requirement and infiltrates in thoracic imaging. LVEF= Left ventricular ejection fraction. ⁴ Neurologic involvement: seizures (n=3), optic neuritis (n=1), meningismus (n=1), headache not included. ⁵Acute Kidney Injury (AKI) was defined as an increase greater than two times the upper limit of the reference range for gender and age. ⁶ ICU: intensive care unit.
* Comparison Cluster 1 vs. cluster 2with Fisher exact test/ Mann-Whitney test